{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immune+Response&page=2",
    "query": {
      "condition": "Human Immune Response",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immune+Response&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T00:06:44.298Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03478891",
      "title": "Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Immune Responses to Vaccine"
      ],
      "interventions": [
        {
          "name": "VRC-EBOMAB092-00-AB (MAb114)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 19,
      "start_date": "2018-05-16",
      "completion_date": "2019-03-20",
      "has_results": true,
      "last_update_posted_date": "2020-10-26",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03478891"
    },
    {
      "nct_id": "NCT01381029",
      "title": "Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza, Human",
        "Human Immunodeficiency Virus I Infection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "George Washington University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 74,
      "start_date": "2009-09",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2023-05-19",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01381029"
    },
    {
      "nct_id": "NCT03520660",
      "title": "People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Hepatitis C, Chronic",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Epclusa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 121,
      "start_date": "2018-10-19",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520660"
    },
    {
      "nct_id": "NCT02902120",
      "title": "HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C",
        "Renal Insufficiency, Chronic",
        "Disorder of Transplanted Kidney"
      ],
      "interventions": [
        {
          "name": "Post-transplant Grazoprevir and Elbasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-05-01",
      "completion_date": "2022-06-08",
      "has_results": true,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02902120"
    },
    {
      "nct_id": "NCT03982069",
      "title": "Immunologic Response to FluMist vs. Flucelvax",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza, Human",
        "Immune Response"
      ],
      "interventions": [
        {
          "name": "FluMist live attenuated influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flucelvax inactivated influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Richard Zimmerman MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "4 Years to 21 Years"
      },
      "enrollment_count": 465,
      "start_date": "2019-09-20",
      "completion_date": "2020-12-09",
      "has_results": true,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03982069"
    },
    {
      "nct_id": "NCT00076427",
      "title": "Leukapheresis for Research on HCV-Coinfected Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C",
        "HIV Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 327,
      "start_date": "2004-01-14",
      "completion_date": "2015-06-09",
      "has_results": false,
      "last_update_posted_date": "2017-10-06",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076427"
    },
    {
      "nct_id": "NCT05972993",
      "title": "A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "mRNA-CR-04 vaccine 10μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-CR-04 vaccine 30μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-CR-04 vaccine 100μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "mRNA-CR-04 vaccine 3μg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 114,
      "start_date": "2023-08-07",
      "completion_date": "2024-10-14",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05972993"
    },
    {
      "nct_id": "NCT00001116",
      "title": "A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tumor Necrosis Factor soluble receptor-immunoadhesin complex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": null,
      "completion_date": "2000-06",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 3,
      "location_summary": "Honolulu, Hawaii • New York, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001116"
    },
    {
      "nct_id": "NCT00100633",
      "title": "Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "CpG7909 oligodeoxynucleotides (ODN)",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis B virus vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-12",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2008-10-01",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100633"
    },
    {
      "nct_id": "NCT00959049",
      "title": "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "CSL's Influenza Virus Vaccine (Afluria)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Virus Vaccine (Fluzone)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 1474,
      "start_date": "2009-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2017-05-16",
      "last_synced_at": "2026-06-11T00:06:44.298Z",
      "location_count": 23,
      "location_summary": "Chandler, Arizona • Harrisburg, Arkansas • Jonesboro, Arkansas + 16 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Harrisburg",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mountain Home",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00959049"
    }
  ]
}